Related references
Note: Only part of the references are listed.A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study
M. Barone et al.
JOURNAL OF VIRAL HEPATITIS (2018)
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naive patients: Findings from two randomized trials
Edward Tam et al.
LIVER INTERNATIONAL (2018)
Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir
Zobair M. Younossi et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2018)
A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects
Polina German et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection
Massimo Colombo et al.
ANNALS OF INTERNAL MEDICINE (2017)
Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients
Lisa Backus et al.
ANTIVIRAL THERAPY (2017)
Reinventing HCV Treatment: Past and Future Perspectives
Wendy Carter et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study
E. B. Tapper et al.
JOURNAL OF VIRAL HEPATITIS (2017)
Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease
Satoru Hagiwara et al.
ONCOLOGY (2017)
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection
Edward J. Gane et al.
GASTROENTEROLOGY (2017)
Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders
C. E. Walsh et al.
HAEMOPHILIA (2017)
The Safety and Effectiveness of Ledipasvir-Sofosbuvir in Adolescents 12-17 Years Old With Hepatitis C Virus Genotype 1 Infection
William F. Balistreri et al.
HEPATOLOGY (2017)
Eight Weeks of Ledipasvir/Sofosbuvir Is Effective for Selected Patients With Genotype 1 Hepatitis C Virus Infection
Kris V. Kowdley et al.
HEPATOLOGY (2017)
Safety and Efficacy of Current Direct-Acting Antiviral Regimens in Kidney and Liver Transplant Recipients With Hepatitis C: Results From the HCV-TARGET Study
Varun Saxena et al.
HEPATOLOGY (2017)
Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis
Vinicius L. Ferreira et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2017)
Real-world effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection within national hepatitis C elimination program in the country of Georgia
T. Tsertsvadze et al.
JOURNAL OF HEPATOLOGY (2017)
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome
Stefan Zeuzem et al.
JOURNAL OF HEPATOLOGY (2017)
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir
David Wyles et al.
JOURNAL OF HEPATOLOGY (2017)
Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens
Norio Akuta et al.
JOURNAL OF MEDICAL VIROLOGY (2017)
Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients
Hiromi Kan et al.
JOURNAL OF MEDICAL VIROLOGY (2017)
Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting
Faisal Abaalkhail et al.
TRANSPLANTATION (2017)
Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naive or Experienced Patients
Mindie H. Nguyen et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Effectiveness of 8-or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients
M. P. Curry et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection
A. Mangia et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study
Jordan J. Feld et al.
CLINICAL INFECTIOUS DISEASES (2017)
Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection
M. Cornberg et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection
C. A. M. Stedman et al.
HAEMOPHILIA (2016)
Safety and Efficacy of Ledipasvir-Sofosbuvir in Black Patients With Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data
Julius M. Wilder et al.
HEPATOLOGY (2016)
The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study
Zobair M. Younossi et al.
LIVER INTERNATIONAL (2016)
Comparative effectiveness of ledipasvir/sofosbuvir±ribavirin vs. ombitasvir/paritaprevir/ritonavir plus dasabuvir±ribavirin in 6961 genotype 1 patients treated in routine medical practice
L. I. Backus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir
Guofeng Cheng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir
Curtis Cooper et al.
CLINICAL INFECTIOUS DISEASES (2016)
Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C
Polina German et al.
CLINICAL PHARMACOKINETICS (2016)
Baseline Creatinine Clearance Is a Predictor of Worsening Renal Function While on Treatment With Sofosbuvir-Ledipasvir
Russell Rosenblatt et al.
GASTROENTEROLOGY (2016)
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2016)
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response
Norah A. Terrault et al.
GASTROENTEROLOGY (2016)
Ledipasvir Plus Sofosbuvir for 12 Weeks in Patients With Hepatitis C Genotype 4 Infection
Armand Abergel et al.
HEPATOLOGY (2016)
Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older
Sammy Saab et al.
HEPATOLOGY (2016)
Evaluation of Proton Pump Inhibitor Use on Treatment Outcomes With Ledipasvir and Sofosbuvir in a Real-World Cohort Study
Elliot B. Tapper et al.
HEPATOLOGY (2016)
Real-World Effectiveness of Ledipasvir/Sofosbuvir in 4,365 Treatment-Naive, Genotype 1 Hepatitis C-Infected Patients
Lisa I. Backus et al.
HEPATOLOGY (2016)
Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2016)
Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus
Z. M. Younossi et al.
JOURNAL OF VIRAL HEPATITIS (2016)
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies
M. Mizokami et al.
JOURNAL OF VIRAL HEPATITIS (2016)
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study
Armand Abergel et al.
LANCET INFECTIOUS DISEASES (2016)
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns et al.
LANCET INFECTIOUS DISEASES (2016)
Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES
Adeel A. Butt et al.
LIVER INTERNATIONAL (2016)
Sofosbuvir Plus Ledispasvir for Recurrent Hepatitis C in Liver Transplant Recipients
Ryan M. Kwok et al.
LIVER TRANSPLANTATION (2016)
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
Brian J. Kirby et al.
CLINICAL PHARMACOKINETICS (2015)
Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy
Avik Majumdar et al.
DRUGS (2015)
Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C
Gillian M. Keating
DRUGS (2015)
Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection
Edward J. Gane et al.
GASTROENTEROLOGY (2015)
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton et al.
GASTROENTEROLOGY (2015)
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
Saleh A. Alqahtani et al.
HEPATOLOGY (2015)
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
David Wyles et al.
HEPATOLOGY (2015)
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1,-2, and-3 clinical trials
Zobair M. Younossi et al.
HEPATOLOGY (2015)
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis
K. Rajender Reddy et al.
HEPATOLOGY (2015)
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
Marc Bourliere et al.
LANCET INFECTIOUS DISEASES (2015)
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
Masashi Mizokami et al.
LANCET INFECTIOUS DISEASES (2015)
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
Anita Kohli et al.
LANCET INFECTIOUS DISEASES (2015)
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection
Kris V. Kowdley et al.
OPEN FORUM INFECTIOUS DISEASES (2015)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Share Paper
